BioCentury
ARTICLE | Product Development

CEOs, VCs split on blame for DSMB debacle, aligned on AZ vaccine efficacy

Industry leaders weigh in on whether the pharma’s disagreement with its DSMB was par for the course or an aberration

March 25, 2021 3:50 AM UTC

The fallout from AstraZeneca’s public clash with the DSMB of its U.S. Phase III trial will hurt the company individually more than biopharma as a whole. But the incident chips away at the broad goodwill earned during the pandemic, and stokes the fires of vaccine hesitancy, industry leaders told BioCentury.

There’s no evidence of outright malfeasance, and the vaccine’s safety and efficacy is not in doubt, according to 13 biopharma CEOs and VCs who spoke with BioCentury. ...

BCIQ Company Profiles

AstraZeneca plc